312 related articles for article (PubMed ID: 28735662)
1. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
[TBL] [Abstract][Full Text] [Related]
2. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
3. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases.
Paiella S; Landoni L; Tebaldi S; Zuffante M; Salgarello M; Cingarlini S; D'Onofrio M; Parisi A; Deiro G; Manfrin E; Bianchi B; Montagnini G; Crinò SF; Bassi C; Salvia R
Neuroendocrinology; 2022; 112(2):143-152. PubMed ID: 33508821
[TBL] [Abstract][Full Text] [Related]
4. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
6. Localization of Unknown Primary Site with
Menda Y; O'Dorisio TM; Howe JR; Schultz M; Dillon JS; Dick D; Watkins GL; Ginader T; Bushnell DL; Sunderland JJ; Zamba GKD; Graham M; O'Dorisio MS
J Nucl Med; 2017 Jul; 58(7):1054-1057. PubMed ID: 28153957
[TBL] [Abstract][Full Text] [Related]
7. Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment.
Mapelli P; Partelli S; Salgarello M; Doraku J; Pasetto S; Rancoita PMV; Muffatti F; Bettinardi V; Presotto L; Andreasi V; Gianolli L; Picchio M; Falconi M
Nucl Med Commun; 2020 Sep; 41(9):896-905. PubMed ID: 32796478
[TBL] [Abstract][Full Text] [Related]
8. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
[TBL] [Abstract][Full Text] [Related]
9. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
[TBL] [Abstract][Full Text] [Related]
10. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT and 68Ga-DOTATOC PET/CT in Diffuse Pancreatic Neuroendocrine Tumor.
Ji X; Dong A; He Q; Dong H; Zuo C
Clin Nucl Med; 2020 May; 45(5):e245-e248. PubMed ID: 32049733
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performances of 68Ga-DOTATOC versus 18Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumours and interrelationship with histological features.
Lococo F; Rapicetta C; Mengoli MC; Filice A; Paci M; Di Stefano T; Coruzzi C; Versari A
Interact Cardiovasc Thorac Surg; 2019 Jun; 28(6):957-960. PubMed ID: 30753507
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
14. Metastasis From Clear Cell Renal Cell Carcinoma Mimicking Well-Differentiated Pancreatic Neuroendocrine Tumor at 18F-FDG and 68Ga-DOTATOC PET/CT.
Guglielmo P; Pesella F; Sartorello A; El Khouzai B; Berti S; Muccioli S; Gregianin M
Clin Nucl Med; 2022 Jul; 47(7):e498-e499. PubMed ID: 35675141
[TBL] [Abstract][Full Text] [Related]
15. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H
Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin.
Binse I; Poeppel TD; Ruhlmann M; Ezziddin S; Görges R; Sabet A; Beiderwellen K; Bockisch A; Rosenbaum-Krumme SJ
J Nucl Med; 2016 Oct; 57(10):1512-1517. PubMed ID: 27033897
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors.
Zhou Z; Wang Z; Zhang B; Wu Y; Li G; Wang Z
Front Endocrinol (Lausanne); 2021; 12():727327. PubMed ID: 34539577
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.
Veenstra EB; de Groot DJA; Brouwers AH; Walenkamp AME; Noordzij W
Clin Nucl Med; 2021 Mar; 46(3):195-200. PubMed ID: 33323729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]